CT–MR fusion has become a Fulvestrant solubility dmso valuable tool in postimplant assessment and improves accuracy of postimplant dosimetry compared with approaches that use CT imaging only [11], [12] and [13]. Because MRI is limited by cost and availability, exploration of other imaging modalities may be helpful. Information from the preoperative transrectal ultrasound (TRUS), such as prostate length, shape, and volume, can be incorporated into postimplant assessment and may be an improvement over the use of CT imaging alone. A recent study by Smith et al. (8) in patients undergoing TRUS, CT, and MRI 30 days after BT showed less contouring variability and

closer correspondence between TRUS and MRI than that between either of these modalities and CT. This suggests that TRUS may be a viable and convenient alternative to MRI in settings where MRI is not available and should improve on the accuracy of CT-based contouring. The purpose of this study is to compare dosimetry obtained using fusion of the preimplant TRUS and Day 30 postimplant CT (CT–TRUS fusion) to fusion of the Day 30 CT to MRI (CT–MR fusion). Twenty men undergoing permanent 125I seed BT at the British Columbia

Cancer Agency Center for the Southern Interior between January and June 2011 were included in this study. No patients received androgen deprivation therapy (ADT) or external beam radiotherapy. The prescription dose of the 125I ROS1 BT implant was 144 Gy. Loose seeds were used for all 20 patients. Patients were eligible if urethrography was performed at the time of

Osimertinib preoperative TRUS and if catheterization was performed with CT imaging 30 days postimplant. All patients at our institution undergo TRUS planning before implantation, generating axial images every 5 mm, including one slice above and below the prostate gland. Urethrography with aerated gel is performed for planning purposes to permit limitation of the urethral dose to 125% of the prescribed dose in the preplan. CT and MRI are generally performed 30 days postimplant, using the following MR sequence: fast spin-echo T2-weighted (1.5 T), repetition time = 4500 ms, echo time = 90 ms, echo train length = 10, field of view = 20 × 20 cm, 3 mm slice thickness, 0 mm gap, and bandwidth = 80 Hz/pixel. The CT and MR images are manually fused for dosimetric assessment, using the seed positions on CT and signal voids on MR as fiducial markers. Catheterization for urethral identification at the time of the Day 30 CT is performed to facilitate calculation of urethral dose. For this study, the TRUS and CT images were fused manually based on the urethral position as determined by TRUS urethrography and the position of the Foley catheter on 1-month CT. Fusion was performed by overlying the sagittal images in the plane of the urethra to superimpose the urethral curvature to bring the base and apex into alignment (Fig. 1).